1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Vraylar |
| structure | File | |
| classes | List of String, delimiter: , | Atypical antipsychotic • D2/D3/5HT1A partial agonist |
| mechanism | String | |
| uses | String | Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). |
| starting_dose | String | Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. |
| preparations | String | 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules |
| fda_max | String | 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Weeks for psychosis/mood efficacy |
| duration | String | Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) |
| halflife | String | Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses |
| bioavailability | String | Adequate oral bioavailability |
| pregnancy | String | Limited data |
| legal | String | Rx |
